Cargando…

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model

Angiogenesis inhibitors such as lenvatinib and sorafenib, and an immune checkpoint inhibitor (ICI), nivolumab, are used for anticancer therapies against advanced hepatocellular carcinoma (HCC). Combination treatments comprising angiogenesis inhibitors plus ICIs are promising options for improving cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimura, Takayuki, Kato, Yu, Ozawa, Yoichi, Kodama, Kotaro, Ito, Junichi, Ichikawa, Kenji, Yamada, Kazuhiko, Hori, Yusaku, Tabata, Kimiyo, Takase, Kazuma, Matsui, Junji, Funahashi, Yasuhiro, Nomoto, Kenichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272102/ https://www.ncbi.nlm.nih.gov/pubmed/30447042 http://dx.doi.org/10.1111/cas.13806

Ejemplares similares

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8(+) T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
por: Kato, Yu, et al.
Publicado: (2019)

Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
por: Matsuki, Masahiro, et al.
Publicado: (2017)

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
por: Tohyama, Osamu, et al.
Publicado: (2014)

Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies
por: Adachi, Yusuke, et al.
Publicado: (2022)

Multitargeting strategy using lenvatinib and golvatinib: Maximizing anti-angiogenesis activity in a preclinical cancer model
por: Nakazawa, Youya, et al.
Publicado: (2015)

The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
por: Zhu, Jie, et al.
Publicado: (2021)

Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
por: Niwa, Yuki, et al.
Publicado: (2023)

Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
por: Matsuki, Masahiro, et al.
Publicado: (2018)

Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy
por: Ichikawa, Kenji, et al.
Publicado: (2020)

S7-2 From HEPA to sustainable HEPA?
por: Abu-Omar, Karim, et al.
Publicado: (2023)

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
por: Yamamoto, Yuji, et al.
Publicado: (2014)

Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor
por: Nakagawa, Takayuki, et al.
Publicado: (2014)

Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models
por: Ito, Ken, et al.
Publicado: (2015)

Lenvatinib Might Induce Activation of Host Immunity in Patients with Hepatocellular Carcinoma
por: Nagai, Hidenari, et al.
Publicado: (2023)

Active Transport of Hepatotoxic Pyrrolizidine Alkaloids in HepaRG Cells
por: Enge, Anne-Margarethe, et al.
Publicado: (2021)

Structural Design of HEPA Filter
por: Xu, Zhonglin
Publicado: (2013)

O.1.3-7 Hungarian Active Lifestyle (HEPA) Strategy 2033
por: Lacza, Gyöngyvér
Publicado: (2023)

mRNA Expression and Activity of Nucleoside Transporters in Human Hepatoma HepaRG Cells
por: Mayati, Abdullah, et al.
Publicado: (2018)

Health Enhancing Physical Activity Policies in Poland: Findings from the HEPA PAT Survey
por: Romanowska, Aleksandra, et al.
Publicado: (2022)

3D spheroid cultures improve the metabolic gene expression profiles of HepaRG cells
por: Takahashi, Yu, et al.
Publicado: (2015)

HEPA/Vaccine Plan for Indoor Anthrax Remediation
por: Wein, Lawrence M., et al.
Publicado: (2005)

Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma
por: Yamada, Tomoharu, et al.
Publicado: (2023)

The Burdens of Orthopedic Patients and the Value of the HEPAS Approach (Healthy Eating, Physical Activity, and Sleep Hygiene)
por: Briguglio, Matteo
Publicado: (2021)

Okadaic Acid Activates JAK/STAT Signaling to Affect Xenobiotic Metabolism in HepaRG Cells
por: Wuerger, Leonie T. D., et al.
Publicado: (2023)

Lenvatinib induces anticancer activity in gallbladder cancer by targeting AKT
por: Ye, Jianwen, et al.
Publicado: (2021)

Microalgae with Immunomodulatory Activities
por: Riccio, Gennaro, et al.
Publicado: (2019)

Successful Treatment by Surgery and Lenvatinib of a Patient with Adrenal Metastasis of Papillary Thyroid Cancer
por: Nakamura, Hajime, et al.
Publicado: (2020)

Lenvatinib for poorly differentiated carcinoma of the anterior mediastinum
por: Yanagihara, Toyoshi, et al.
Publicado: (2021)

Transcatheter arterial chemoembolization with spherical embolic material for locally advanced breast cancer: first report of HepaSphere™ treatment for primary breast cancer
por: Kennoki, Norifumi, et al.
Publicado: (2016)

The added value of using the HEPA PAT for physical activity policy monitoring: a four-country comparison
por: Gelius, Peter, et al.
Publicado: (2021)

Comparison of gene expression and biotransformation activity of HepaRG cells under static and dynamic culture conditions
por: Duivenvoorde, Loes P. M., et al.
Publicado: (2021)

An ecosystems approach for health-enhancing physical activity promotion: introducing the 11th Conference of HEPA Europe
por: Kovacs, Viktoria A, et al.
Publicado: (2022)

Functional significance of the hepaCAM gene in bladder cancer
por: He, Yunfeng, et al.
Publicado: (2010)

Immunomodulatory activity of interferon-beta
por: Kasper, Lloyd H, et al.
Publicado: (2014)

Immunomodulatory activities of gemifloxacin in mice
por: Umair, Muhammad, et al.
Publicado: (2016)

Investigating the immunomodulatory activities of omadacycline
por: Bryant, Amy E, et al.
Publicado: (2022)

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
por: Funahashi, Yasuhiro, et al.
Publicado: (2014)

Stability of the Aryl hydrocarbon Receptor and its Regulated Genes in the Low activity Variant of Hepa-1 cell line
por: Humphrey-Johnson, Andria, et al.
Publicado: (2015)

Antioxidant and Quinone Reductase Activity of Soyasaponins in Hepa1c1c7 Mouse Hepatocarcinoma Cells
por: Hwang, Eun-Sun
Publicado: (2017)

Differential Metabolisms of Green Leaf Volatiles in Injured and Intact Parts of a Wounded Leaf Meet Distinct Ecophysiological Requirements
por: Matsui, Kenji, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j6h6ob4606lbmn9kisgh9fn2ac